Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$3.76
+4.6%
$5.15
$3.39
$16.00
$40.66M0.8753,936 shs14,193 shs
Journey Medical Co. stock logo
DERM
Journey Medical
$8.02
+1.8%
$6.71
$3.50
$8.24
$186.72M0.8684,079 shs28,648 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$3.78
+8.8%
$3.23
$2.24
$28.93
$173.95M2.87831,064 shs219,759 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$17.66
+3.3%
$13.69
$2.03
$14.36
$165.97M1.1150,104 shs128,976 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-0.83%-5.28%-24.10%-45.61%-68.81%
Journey Medical Co. stock logo
DERM
Journey Medical
+1.29%+16.08%+3.83%+41.04%+118.61%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
+1.46%-2.25%+3.89%-22.54%-86.06%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-1.10%-7.87%+10.90%-0.64%-46.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.5523 of 5 stars
4.43.00.00.02.51.71.3
Journey Medical Co. stock logo
DERM
Journey Medical
2.5762 of 5 stars
3.64.00.00.01.41.70.6
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
3.23 of 5 stars
4.33.00.00.02.71.70.6
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2.83
Moderate Buy$33.00778.83% Upside
Journey Medical Co. stock logo
DERM
Journey Medical
3.20
Buy$9.8823.21% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.60
Moderate Buy$29.56682.93% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AVTX, NLTX, DERM, and FDMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/15/2025
Journey Medical Co. stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/10/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $25.00
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $44.00
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.00
4/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
4/8/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
3/27/2025
Journey Medical Co. stock logo
DERM
Journey Medical
Industrial Alliance Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$10.50
3/27/2025
Journey Medical Co. stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform ➝ Buy$23.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$441K92.20N/AN/A$9.11 per share0.41
Journey Medical Co. stock logo
DERM
Journey Medical
$56.24M3.32$0.28 per share28.37$1.05 per share7.63
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$23K7,603.34N/AN/A$7.20 per share0.52
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)
Journey Medical Co. stock logo
DERM
Journey Medical
-$3.85M-$0.39N/AN/AN/A-31.74%-132.10%-26.90%8/11/2025 (Estimated)
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$100.84M-$3.18N/AN/AN/AN/A-28.00%-26.16%8/14/2025 (Estimated)
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A

Latest AVTX, NLTX, DERM, and FDMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Journey Medical Co. stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
5/12/2025Q1 2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.07-$1.25-$0.18-$1.25N/AN/A
5/8/2025Q1 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A
3/26/2025Q4 2024
Journey Medical Co. stock logo
DERM
Journey Medical
-$0.22$0.08+$0.30$0.08$14.21 million$14.30 million
2/28/2025Q4 2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.80-$0.90-$0.10-$0.90$2.28 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
Journey Medical Co. stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
1.42
1.42
Journey Medical Co. stock logo
DERM
Journey Medical
1.81
1.38
1.03
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
17.33
17.33
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
Journey Medical Co. stock logo
DERM
Journey Medical
7.25%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4010.83 million10.37 millionNot Optionable
Journey Medical Co. stock logo
DERM
Journey Medical
9023.30 million18.14 millionN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.33 million42.85 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$3.76 +0.17 (+4.60%)
As of 01:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$8.02 +0.15 (+1.84%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$3.78 +0.31 (+8.79%)
As of 01:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$17.66 +0.57 (+3.34%)
As of 05/28/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.